Puma Biotechnology Inc (NYSE:PBYI) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Wednesday.

Several other equities analysts have also issued reports on PBYI. Credit Suisse Group restated an “outperform” rating and set a $58.00 target price on shares of Puma Biotechnology in a research report on Tuesday, April 18th. Stifel Nicolaus reiterated a “buy” rating and set a $88.00 price objective on shares of Puma Biotechnology in a report on Wednesday, April 19th. Royal Bank Of Canada set a $40.00 price objective on Puma Biotechnology and gave the company a “hold” rating in a report on Wednesday, May 10th. Zacks Investment Research upgraded Puma Biotechnology from a “hold” rating to a “buy” rating and set a $36.00 price objective on the stock in a report on Tuesday, May 16th. Finally, Citigroup Inc. reiterated a “buy” rating and set a $88.00 price objective on shares of Puma Biotechnology in a report on Monday, May 22nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $109.56.

Puma Biotechnology (NYSE PBYI) traded up 2.11% during mid-day trading on Wednesday, reaching $82.25. 808,741 shares of the company’s stock were exchanged. The stock’s market cap is $3.04 billion. Puma Biotechnology has a 52 week low of $28.35 and a 52 week high of $98.85. The stock has a 50-day moving average price of $88.09 and a 200-day moving average price of $57.55.

Puma Biotechnology (NYSE:PBYI) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by $0.78. On average, analysts forecast that Puma Biotechnology will post ($8.62) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/16/puma-biotechnology-inc-pbyi-downgraded-by-bidaskclub.html.

In other news, SVP Richard Paul Bryce sold 1,998 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $94.48, for a total transaction of $188,771.04. Following the sale, the senior vice president now owns 27,246 shares in the company, valued at approximately $2,574,202.08. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Alan H. Auerbach sold 13,175 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $94.73, for a total value of $1,248,067.75. Following the sale, the insider now owns 4,170,623 shares in the company, valued at approximately $395,083,116.79. The disclosure for this sale can be found here. In the last quarter, insiders have sold 2,010,261 shares of company stock worth $159,425,452. Company insiders own 22.70% of the company’s stock.

Large investors have recently made changes to their positions in the company. Strs Ohio bought a new stake in shares of Puma Biotechnology during the second quarter worth about $122,000. Cubist Systematic Strategies LLC bought a new stake in shares of Puma Biotechnology during the second quarter worth about $146,000. Bank of Montreal Can bought a new stake in shares of Puma Biotechnology during the first quarter worth about $195,000. Alambic Investment Management L.P. bought a new stake in shares of Puma Biotechnology during the first quarter worth about $201,000. Finally, Kazazian Asset Management LLC bought a new stake in shares of Puma Biotechnology during the second quarter worth about $209,000. Institutional investors own 80.98% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.